|
|
DF/HCC News
Divide-and-conquer strategy drives breast cancer breakthroughs Pulling a page from ancient Rome’s military handbook, investigators in the DF/HCC Breast Cancer Program are deploying a divide-and-conquer strategy in the battle against breast cancer
siRNA knockdowns turn up intriguing HER2 targets At best, only 20 to 30 percent of women with HER2-positive breast cancer respond to trastuzumab
Fusion vaccine plus surgery may prove potent combination in renal cell cancer Renal cell cancer (RCC) is a life-threatening malignancy considered incurable in the metastatic setting
Breakefield awarded $5.8 million to study tumors 
DF/HCC member Xandra Breakefield, PhD (MGH) will receive approximately $5.8 million in total costs over five years to study the genetic and cellular factors contributing to the formation and progression of benign tumors in the nervous system
Harvard receives transforming NIH award 
Harvard Medical School has been awarded the Clinical and Translational Science Award (CTSA) from the National Institutes of Health
DePinho awarded $10.8 million to study malignant gliomas 
DF/HCC member Ronald DePinho, MD (DFCI) has successfully renewed funding from the NCI to better understand the pathogenesis of glioblastoma multiforme (GBM)
Two DF/HCC members honored at ASCO annual meeting  Jay Harris, MD (DFCI) and Bruce Johnson, MD (DFCI) were honored at the 2008 meeting of the American Society of Clinical Oncology (ASCO) for their outstanding accomplishments in cancer research
Displaying results 113 to 119 out of 184
|
